Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRONTO: Birtamimab in AL Amyloidosis
NCT02632786Phase 2Completed
- Sponsor
- Prothena Corporation
- Start
- Mar 2016
- Primary completion
- Mar 2018
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial in amyloid light chain amyloidosis comparing NEOD001 with Placebo (2 arms). Primary endpoint: Number of Participants With Cardiac Response and Non-Response at 12 months. Started Mar 2016; status: completed.
02
Drugs
birtamimab
03
Conditions
amyloid light chain amyloidosis
Beyond the preview
Go deeper on NCT02632786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02632786.